10x Genomics, Inc. revenue
10x Genomics, Inc.'s revenue was $643m in fiscal 2025, up 5.2% on the year before. Since fiscal 2017 ($71.1m) it has grown at a compound 31.7% a year. Over the last twelve months it was $617m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71 | 146 | 246 | 299 | 490 | 516 | 619 | 611 | 643 | 617 |
| Growth on the year before | — | +105.8% | +68.1% | +21.5% | +64.1% | +5.3% | +19.8% | −1.3% | +5.2% | — |
| Gross profit | 61 | 118 | 185 | 240 | 416 | 396 | 409 | 414 | 444 | 432 |
| Gross margin | 85.1% | 80.4% | 75.2% | 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% | 70.0% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Product and Service Revenue | $597M | ▼ 2.3% |
| Consumables | $507M | ▲ 2.8% |
| Single Cell Consumables | $363M | ▼ 2.4% |
| Spatial Consumables | $144M | ▲ 18.9% |
| Instruments | $56.8M | ▼ 38.8% |
| Licensing and Royalty Revenue | $46.1M | ▲ 14272.3% |
| Spatial Instruments | $34.1M | ▼ 40.7% |
| Services | $32.7M | ▲ 34.6% |
| Single Cell Instruments | $22.7M | ▼ 35.6% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| Americas | $359M | 55.8% | ▲ 3.2% |
| United States (part of Americas) | $347M | 96.6% | ▲ 3.6% |
| Americas Excluding United States (part of Americas) | $12.3M | 3.4% | ▼ 8.8% |
| EMEA | $162M | 25.2% | ▲ 1.2% |
| Asia Pacific | $122M | 19.0% | ▲ 18.5% |
| China (part of Asia Pacific) | $70.3M | 57.4% | ▲ 22.6% |
| Asia Pacific Excluding China (part of Asia Pacific) | $52.1M | 42.6% | ▲ 13.3% |
From 10x Genomics, Inc.'s 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| 10x Genomics, Inc. | $617m | -4.3% | 2.8% |
| Azenta, Inc. | $614m | 4.9% | -0.9% |
| Veracyte, Inc. | $562m | 17.3% | 19.6% |
| Neogenomics Inc | $788m | 11.1% | 11.1% |
| Repligen Corp | $806m | 13.8% | 7.3% |
| Twist Bioscience Corp | $432m | 19.2% | 22.4% |
Compare with peers
- Azenta, Inc. revenue
- Veracyte, Inc. revenue
- Neogenomics Inc revenue
- Repligen Corp revenue
- Twist Bioscience Corp revenue
Head to head: AZTA vs TXGTXG vs VCYTNEO vs TXGRGEN vs TXG
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies